Tag: ASX: CU6
Clarity and Nucleus RadioPharma scale up manufacturing for cancer treatment
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has entered into a Master Services Agreement (MSA) and Clinical Manufacturing Agreement for the production of 67Cu-SAR-bisPSMA, a radiopharmaceutical treatment for prostate cancer.
Clarity Pharmaceuticals inks clinical supply agreement for prostate cancer imaging products
ASX-listed Clarity Pharmaceuticals has signed a Master Service Agreement and a Clinical Supply Agreement with Siemens Healthineers company PETNET Solutions Inc for the supply expansion of Clarity’s 64Cu SAR-bisPSMA, a diagnostic radiopharmaceutical product for prostate cancer imaging.
Featured Article
“New Starts Here”: AGHA launches national platform for gift and homewares
Australia’s peak organisation for the gift and homewares sector, the Australian Gift & Homewares Association (AGHA), has revealed plans for a major expansion in 2026, introducing Gifted Melbourne 2026 to complement the long-established AGHA Sydney Gift Fair.
